GAS5 and breast carcinoma: Beyond breast cancer, GAS5 is frequently downregulated across a broad spectrum of malignancies, where its loss is associated with dysregulation of cell cycle control, an event that can critically contribute to tumour development and progression [[90], [91], [92], [93]].